The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Inclusion Criteria: * Adenocarcinoma of the prostate with radiographic evidence of metastatic disease. * Willingness to undergo a baseline tumor biopsy. * Castrate levels of testosterone (testosterone \< 50 ng/dL) on androgen deprivation therapy (ADT) with evidence of progression on ADT. GnRH therapy will be continued for those on it at baseline * Patient must have suspected tumor in an area that is safe to biopsy. * Other prior hormonal interventions or experimental approaches are allowed. These therapies must have been discontinued for a minimum of 28 days with cancer progression. * Prior or concurrent use of bisphosphonates is allowed. * One prior non-taxane chemotherapy allowed * ≥ 3 weeks since major surgery; ≥ 4 weeks since radiotherapy; ≥ 8 weeks since prior strontium-89 or samarium 153 * Performance Status: ECOG 0 or 1 * ANC \> 1,500/\_l; platelets \> 100,000/\_l; total Bilirubin \< upper limit of normal; AST and ALT \< 3 x upper limits of normal; creatinine \< 1.5 x upper limits of normal; total fasting cholesterol \< 350 mg/dl; total triglycerides \< 300 mg/dl Exclusion Criteria: * Ongoing oral steroid use. Patients with a history of oral steroid use are eligible as long as the steroids have been discontinued prior to study entry. Ongoing topical and/or inhaled steroid use is allowed. * Prior taxane chemotherapy * Prior mTOR inhibitors (RAD001, rapamycin, CCI-779) * Currently active second malignancy other than non-melanoma skin cancer. * Ongoing peripheral neuropathy of Grade 2